Our Science
Developing an end-to-end solution to reveal and stop chronic and progressive diseases
Our Approach
As our collective understanding of disease continues to grow at an exponential rate, it has become evident that the transition from health-to-disease isn’t just a sharp change; rather, the health-to-disease axis is a continuum that ranges from early, silent stages to advanced, symptomatic and irreversible ones.
This evolving perspective challenges traditional approaches of patient monitoring, screening, diagnosis and treatment, and underscores the need to rethink how we address disease progression.
At Etiome, we believe that as diseases progress, their dynamic underlying biology will mandate Biostaged Medicines, stage-specific therapies delivered to the right patient population at the right time that slow or stop the progression of disease.
We have shown for the first time, and across a number of conditions, that previously unappreciated substages of disease can be defined by clear Biostaged Markers, molecular and cellular signatures indicating where a patient resides along the disease journey. These unprecedented insights allow us to identify even silent stages of disease, before the appearance of outward physiological manifestations or obvious symptoms.
Temporal Biodynamics™ Platform
With access to deep, expansive, multimodal population-level data, the ability to engage directly with vast groups of patients and the advent of biomolecular single-cell omics, we can now develop preemptive medicines that promise better health outcomes. Our Temporal Biodynamics™ platform enables us to accurately characterize the stages of disease progression, selectively engage patients across disease stages and create targeted medicines designed to alter the course of diseases, even at their earliest stages.
Process & Platform Overview
Changing the way disease is studied and characterized to improve the way it’s treated
Our Temporal Biodynamics™ platform leverages complex clinical, cellular and molecular data to characterize biology at scale and over time, quickly uncovering the temporal biodynamics of disease progression without the need for protracted longitudinal studies. This enables us to confidently identify therapeutically relevant disease modulators and linked Biostaged Markers, facilitating the development of Biostaged Medicines for critical intervention windows where they can be most effective.
How It Works
Step 1: Predict the Right Time
Leverage artificial intelligence to forecast when individuals are likely to progress further into disease
We have developed proprietary algorithms and software that can analyze real-world, population-level data to map individuals along a broad spectrum of health and disease substages. This provides a deep understanding of health dynamics over time across major disease areas. We have also gathered unique cellular and molecular data from biospecimens across all stages of disease, including early, silent substages, collected through enhanced forecasting-enabled studies. These data and derived biological characterization are critical for the discovery of Biostaged Medicines and efficient clinical translation.
Step 2: Biostage the Right Patients
Characterize the continuum of disease and define patient substages with Biostaged Markers
Our proprietary phenotype-aware AI integrates these multi-scale datasets to isolate and uncover underlying temporal shifts in thousands of genes and proteins specific to each disease. The newly discovered biological shifts characterizing the continuous biology of a disease reveal unique Biostaged Markers, stage-specific biomarkers that indicate where a patient resides along the disease journey, and putative therapeutic targets. Equipped with these markers of progression, we can more precisely pinpoint individuals most likely to benefit from stage-specific interventions.
Step 3: Intervene with the Right Medicine
Identify and develop Biostaged Medicines
With a detailed understanding of disease substages, we can identify the drivers of and protectors against disease progression to inform the development of Biostaged Medicines. Our custom-built, proprietary assays, informed by these dynamic biological representations, enable us to validate these potentially transformative therapeutics and advance them toward clinical use to ensure the right patients get the right medicines at the right time.
Applications
We are initially focused on addressing serious and progressive conditions within metabolic, neurodegenerative, pre-cancerous and autoimmune disease areas.
We aim to apply our platform to conditions that impact large populations where there is a clear unmet need, long periods of progression, and clear opportunities to provide benefits to patients through Biostaged Medicines.